Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

QIAGEN – QIAstat-Dx Respiratory SARS-CoV-2 Panel

Qiagen will develop a COVID-19 test, QIAstat-Dx RPS2, to be added to the QIAstat-Dx Respiratory Panel. The device is used to run FDA-cleared tests for 21 respiratory pathogens. The device features easy-to-use molecular testing with novel workflows.

Emergency Use Authorization

On March 30, 2020, FDA issued an Emergency Use Authorization (EUA) to allow QIAGEN's QIAstat-Dx Respiratory SARS-CoV-2 Panel to be used to detect and differentiate nucleic acid from multiple respiratory viral and bacterial organisms, including the SARS-CoV-2 virus.


  • This page last reviewed: October 26, 2020